BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tafamidis regulatory update

FDA refused to file an NDA from Pfizer for tafamidis to treat transthyretin (TTR) familial amyloid polyneuropathy (FAP). According to...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >